Expert consensus on the value and strategies of precise drug administration for multi-ethnic populations in China

doi:10.12092/j.issn.1009-2501.2026.01.001

Abstract

Abstract:

The level of precision medication for multiple ethnic groups is crucial to the overall health and ethnic unity of our country, and is of vital importance to the realization of "Healthy China 2030" and the development and security of our country. To improve the health level of multiple ethnic groups, this article takes precision medication research as the core, elaborates on its significance in enhancing the rationality and safety of medication, and emphasizes the necessity of precision medication research for ethnic minorities. The aim is to establish a consensus on precision medication research based on the clinical pharmacokinetic and pharmacodynamic variations of multiple ethnic groups, in order to better ensure the efficacy and safety of medication for different ethnic groups. This consensus systematically reviews the general situation of clinical pharmacokinetic and pharmacodynamic variations in multiple ethnic groups, and analyzes the causes and mechanisms of variations from significant influencing factors such as genetic factors, intestinal flora, pathological and physiological states, high-altitude hypoxic environment, and dietary habits. Based on the existing evidence from clinical pharmacokinetics and pharmacodynamics studies of multi-ethnic populations, as well as the latest research techniques (physiologically pharmacokinetic virtual humans) strategies and considerations, the value and strategies of ethnic-specific drug use research are clarified. After thorough discussion, a consensus was reached, providing theoretical basis and practical guidance for the research on precise drug use in multi-ethnic populations.

Key words: precision medication, multiple ethnic groups, pharmacokinetics and pharmacodynamics, influencing factors, expert consensus

CLC Number:

R969

Yuan LIU, Cheng CUI, Miao YU, Wenyu JIN, Yinliang BAI, Yabin DUAN, Cao FANG, Jianchang HE, Yan HE, Hua HUANG, Shixia HUO, Yang JIN, Lin JIANG, Zhe JIANG, Zheng JIAO, Xuejun LI, Xiangyang LI, Hongjian LI, Lihong LIU, Yang LIU, Hongqiang QIU, Feng SUN, Jianjun SUN, Xuechang WANG, Jianhua WANG, Zhenlei WANG, Shijie WEI, Xiaowen YAN, Lei ZHANG, Xuenong ZHANG, Yuxin ZHANG, Jun ZHAO, Jiye YIN, Ru YAN, Xinchun WANG, Dongyang LIU. Expert consensus on the value and strategies of precise drug administration for multi-ethnic populations in China[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(1): 1-13.

Figures/Tables 2

References 96

1	Pacanowski M, Liu Q. Precision medicine 2030[J]. Clin Pharmacol Ther, 2020, 107 (1): 62- 64. doi: 10.1002/cpt.1675
2	Guo R. China Ethnic Statistical Yearbook 2020 [M]. 2020.
3	Li J, Lou H, Yang X, et al. Genetic architectures of ADME genes in five Eurasian admixed populations and implications for drug safety and efficacy[J]. J Med Genet, 2014, 51 (9): 614- 622. doi: 10.1136/jmedgenet-2014-102530
4	Niu R, Guo L, Dong X, et al. Analysis of the difference in SLCO1B1 and APOE gene polymorphisms between Mongolian and Han populations[J]. Pharmacogenomics, 2022, 23 (14): 783- 790. doi: 10.2217/pgs-2022-0072
5	Qi G, Han C, Zhou Y, et al. Allele and genotype frequencies of CYP3A4, CYP3A5, CYP3A7, and GSTP1 gene polymorphisms among mainland Tibetan, Mongolian, Uyghur, and Han Chinese populations[J]. Clin Exp Pharmacol Physiol, 2022, 49 (2): 219- 227. doi: 10.1111/1440-1681.13604
6	Zhang J, Zhu J, Yao X, et al. Pharmacokinetics of lidocaine hydrochloride metabolized by CYP3A4 in Chinese Han volunteers living at low altitude and in Native Han and Tibetan Chinese volunteers living at high altitude[J]. Pharmacology, 2016, 97 (3/4): 107- 113. doi: 10.1159/000443332
7	Khoury MJ, Bowen S, Dotson WD, et al. Health equity in the implementation of genomics and precision medicine: a public health imperative[J]. Genet Med, 2022, 24 (8): 1630- 1639. doi: 10.1016/j.gim.2022.04.009
8	Jin T, Zhang M, Yang H, et al. Genetic polymorphisms of the drug-metabolizing enzyme CYP2C19 in the Uyghur population in northwest China[J]. Xenobiotica, 2016, 46 (7): 634- 640. doi: 10.3109/00498254.2015.1102986
9	Liu Y, Xie J, Wang M, et al. Genomic insights into the population history and biological adaptation of southwestern Chinese Hmong-Mien people[J]. Front Genet, 2021, 12, 815160. doi: 10.1101/2021.10.16.463767
10	Ma X, Yang W, Gao Y, et al. Genetic origins and sex-biased admixture of the huis[J]. Mol Biol Evol, 2021, 38 (9): 3804- 3819. doi: 10.1093/molbev/msab158
11	Zhang Z, Zhang Y, Wang Y, et al. The Tibetan-Yi region is both a corridor and a barrier for human gene flow[J]. Cell Rep, 2022, 39 (4): 110720. doi: 10.1016/j.celrep.2022.110720
12	Zhang J, Wang H, Niu G, et al. Deciphering DMET genetic data: comprehensive assessment of Northwestern Han, Tibetan, Uyghur populations and their comparison to eleven 1000 genome populations[J]. Artif Cells Nanomed Biotechnol, 2018, 46 (sup3): S1176- s1185. doi: 10.1080/21691401.2018.1533849
13	He N, Yan FX, Huang SL, et al. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population[J]. Eur J Clin Pharmacol, 2002, 58 (1): 15- 18. doi: 10.1007/s00228-002-0425-x
14	Lai Y, Zhang J, Wang YX, et al. CYP3A5*3 and MDR-1 C3435T single nucleotide polymorphisms in six Chinese ethnic groups[J]. Pharmazie, 2011, 66 (2): 136- 140.
15	Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele[J]. J Pharmacol Exp Ther, 1997, 281 (1): 604- 609. doi: 10.1016/S0022-3565(24)36606-6
16	Yin SJ, Ni YB, Wang SM, et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations[J]. J Clin Pharm Ther, 2012, 37 (3): 364- 369. doi: 10.1111/j.1365-2710.2011.01298.x
17	Chang XY, Guo T, Xia DY. Pharmacokinetics of Tinidazole in Chinese subjects: comparison of Mongolian, Korean, Hui, Uighur and Han nationalities[J]. J Pharm Pharm Sci, 2009, 12 (2): 175- 180.
18	Guo T, Mao GF, Xia DY, et al. Pharmacokinetics of midazolam tablet in different Chinese ethnic groups[J]. J Clin Pharm Ther, 2011, 36 (3): 406- 411. doi: 10.1111/j.1365-2710.2010.01178.x
19	Yang L, Guo T, Xia DY, et al. Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China[J]. J Clin Pharm Ther, 2012, 37 (2): 226- 231. doi: 10.1111/j.1365-2710.2011.01279.x
20	Lai Y, Huang M, Li H, et al. Distinct genotype distribution and haplotype profiles in MDR1 gene among Chinese Han, Bai, Wa and Tibetan ethnic groups[J]. Pharmazie, 2012, 67 (11): 938- 941.
21	Sun B, Thao T, Culhane-Pera K, et al. Advancing pharmacogenomic research in US Hmong populations: prevalence of key single nucleotide variations in California Hmong[J]. Front Pharmacol, 2024, 15, 1432906. doi: 10.3389/fphar.2024.1432906
22	段婧, 蔡乐, 肖义泽, 等. 云南省西双版纳州傣族与汉族代谢综合征及相关疾病的流行现状[J]. 现代预防医学, 2013, 40 (1): 79- 81,85.
23	董哲, 康文玉, 余文, 等. 云南省18个少数民族2009-2018年乙型病毒性肝炎流行趋势[J]. 中华疾病控制杂志, 2020, 24 (2): 139- 144. doi: 10.16462/j.cnki.zhjbkz.2020.02.004
24	Džidić-Krivić A, Kusturica J, Sher EK, et al. Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs[J]. Drug Metab Rev, 2023, 55 (1/2): 126- 139.
25	Flowers SA, Bhat S, Lee JC. Potential implications of gut microbiota in drug pharmacokinetics and bioavailability[J]. Pharmacotherapy, 2020, 40 (7): 704- 712. doi: 10.1002/phar.2428
26	Li X, Liu L, Cao Z, et al. Gut microbiota as an "invisible organ" that modulates the function of drugs[J]. Biomed Pharmacother, 2020, 121, 109653.
27	Noh K, Kang YR, Nepal MR, et al. Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs[J]. Arch Pharm Res, 2017, 40 (12): 1345- 1355. doi: 10.1007/s12272-017-0986-y
28	Enright EF, Govindarajan K, Darrer R, et al. Gut microbiota-mediated bile acid transformations alter the cellular response to multidrug resistant transporter substrates in vitro: focus on P-glycoprotein[J]. Mol Pharm, 2018, 15 (12): 5711- 5727. doi: 10.1021/acs.molpharmaceut.8b00875
29	Feng W, Liu J, Ao H, et al. Targeting gut microbiota for precision medicine: focusing on the efficacy and toxicity of drugs[J]. Theranostics, 2020, 10 (24): 11278- 11301. doi: 10.7150/thno.47289
30	Shen Y, Liu J, Yao B, et al. Non-alcoholic fatty liver disease changes the expression and activity of hepatic drug-metabolizing enzymes and transporters in rats[J]. Toxicol Lett, 2024, 396, 36- 47. doi: 10.1016/j.toxlet.2024.04.010
31	Chen R, Duan ZY, Duan XH, et al. Progress in research on gut microbiota in ethnic minorities in China and consideration of intervention strategies based on ethnic medicine: a review[J]. Front Cell Infect Microbiol, 2022, 12, 1027541. doi: 10.3389/fcimb.2022.1027541
32	Lin D, Wang R, Luo J, et al. The core and distinction of the gut microbiota in Chinese populations across geography and ethnicity[J]. Microorganisms, 2020, 8 (10): 1579. doi: 10.3390/microorganisms8101579
33	Rao J, Qiu P, Zhang Y, et al. Gut microbiota trigger host liver immune responses that affect drug-metabolising enzymes[J]. Front Immunol, 2024, 15, 1511229. doi: 10.3389/fimmu.2024.1511229
34	Ouyang Y, Pinstrup-Andersen P. Health inequality between ethnic minority and Han populations in China[J]. World Development, 2012, 40 (7): 1452- 1468. doi: 10.1016/j.worlddev.2012.03.016
35	Maher D, Ailabouni N, Mangoni AA, et al. Alterations in drug disposition in older adults: a focus on geriatric syndromes[J]. Expert Opin Drug Metab Toxicol, 2021, 17 (1): 41- 52. doi: 10.1080/17425255.2021.1839413
36	Bai X, Liu G, Yang J, et al. Gut microbiota as the potential mechanism to mediate drug metabolism under high-altitude hypoxia[J]. Curr Drug Metab, 2022, 23 (1): 8- 20.
37	Min Q, Feng SL, Lu H, et al. Modulation of drug-metabolizing enzymes and transporters under hypoxia environment[J]. Sheng Li Xue Bao, 2019, 71 (2): 336- 342.
38	Qiu F, Sun Y, Li W, et al. A review on drug-metabolizing enzymes, transporters, and gut microbiota on pharmacokinetics in high-altitude environment [J]. Curr Drug Metab, 2025, doi: 10.2174/0113892002356402250130075811.
39	Li X, Zhang J, Liu G, et al. High altitude hypoxia and oxidative stress: the new hope brought by free radical scavengers[J]. Life Sci, 2024, 336, 122319. doi: 10.1016/j.lfs.2023.122319
40	Valencia-Cervantes J, Huerta-Yepez S, Aquino-Jarquín G, et al. Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia-inducible factor 1α-mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation[J]. Oncol Rep, 2019, 41 (1): 178- 190.
41	Zhou X, Nian Y, Qiao Y, et al. Hypoxia plays a key role in the pharmacokinetic changes of drugs at High Altitude[J]. Curr Drug Metab, 2018, 19 (11): 960- 969. doi: 10.2174/1389200219666180529112913
42	Morris ME, Ren T. Diet/Nutrient Interactions With Drug Transporters [M]// Drug Transporters, 2022: 515-541.
43	Lu J, Yang T, Tang D, et al. Associations between major dietary patterns and blood pressure among Southwest Chinese: a cross-sectional analysis based on the China Multi-Ethnic Cohort (CMEC) study[J]. Nutr Metab Cardiovasc Dis, 2023, 33 (5): 987- 997. doi: 10.1016/j.numecd.2023.01.023
44	Liu D, Liang XC. New developments in the pharmacodynamics and pharmacokinetics of combination of Chinese medicine and Western medicine[J]. Chin J Integr Med, 2017, 23 (4): 312- 319. doi: 10.1007/s11655-016-2271-1
45	Zhou Y, Arribas GH, Turku A, et al. Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine[J]. Sci Adv, 2021, 7 (36): eabi6856. doi: 10.1126/sciadv.abi6856
46	Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response[J]. Annu Rev Pharmacol Toxicol, 2001, 41, 815- 850. doi: 10.1146/annurev.pharmtox.41.1.815
47	Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies[J]. Clin Pharmacol Ther, 2008, 84 (3): 417- 23. doi: 10.1038/clpt.2008.141
48	Lam MP, Cheung BM. The pharmacogenetics of the response to warfarin in Chinese[J]. Br J Clin Pharmacol, 2012, 73 (3): 340- 347. doi: 10.1111/j.1365-2125.2011.04097.x
49	Wang L, Aikemu A, Yibulayin A, et al. Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China[J]. BMC Genet, 2015, 16, 66. doi: 10.1186/s12863-015-0232-x
50	Guo L, Zhang W, Meng W, et al. Very important pharmacogenes polymorphism landscape and potential clinical relevance in the Chinese Mongolian[J]. Gene, 2023, 850, 146960. doi: 10.1016/j.gene.2022.146960
51	He Y, Wu W, Zheng HM, et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models[J]. Nat Med, 2018, 24 (10): 1532- 1535. doi: 10.1038/s41591-018-0164-x
52	Chrysostomou D, Roberts LA, Marchesi JR, et al. Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy[J]. Gastroenterology, 2023, 164 (2): 198- 213. doi: 10.1053/j.gastro.2022.10.018
53	Yifei JIA, Panpan W, Yijia C, et al. Advances in gut microbial drug metabolism[J]. Prog Pharmaceut Sci, 2020, 44 (2): 83- 99.
54	Xia B, Li B, Wang H, et al. Characteristics of gut microbiota in different regions and ethnic minorities of China and their associations with diseases [J/OL]. Authorea, 2025, http://www.authorea.com/doi/full/10.22541/au.
55	Zhao Q, Chen Y, Huang W, et al. Drug-microbiota interactions: an emerging priority for precision medicine[J]. Signal Trans Targ Thery, 2023, 8 (1): 386. doi: 10.1038/s41392-023-01619-w
56	Tao L, Tian T, Liu L, et al. Cohort profile: the Xinjiang Multiethnic Cohort (XMC) study[J]. BMJ Open, 2022, 12 (5): e048242. doi: 10.1136/bmjopen-2020-048242
57	Williamson DM, Marrie RA, Ashley-Koch A, et al. Interaction of HLA-DRB1*1501 and TNF-Alpha in a population-based case-control study of multiple sclerosis[J]. Immunol Infect Dis, 2013, 1 (1): 10- 17. doi: 10.13189/iid.2013.010102
58	Duo D, Duan Y, Zhu J, et al. New strategy for rational use of antihypertensive drugs in clinical practice in high-altitude hypoxic environments[J]. Drug Metab Rev, 2023, 55 (4): 388- 404. doi: 10.1080/03602532.2023.2250930
59	Peng W, Li K, Yan AF, et al. Prevalence, management, and associated factors of obesity, hypertension, and diabetes in Tibetan population compared with China overall[J]. Int J Environ Res Public Health, 2022, 19 (14): 8787. doi: 10.3390/ijerph19148787
60	Niederberger E, Parnham MJ. The impact of diet and exercise on drug responses[J]. Int J Mol Sci, 2021, 22 (14): 7692. doi: 10.3390/ijms22147692
61	Aoyama T, Ishida Y, Kaneko M, et al. Pharmacokinetics and pharmacodynamics of meloxicam in East Asian populations: the role of ethnicity on drug response[J]. CPT Pharmacometrics Syst Pharmacol, 2017, 6 (12): 823- 832. doi: 10.1002/psp4.12259
62	Le TT, Mcgrath SR, Fasinu PS. Herb-drug interactions in neuropsychiatric pharmacotherapy-A review of clinically relevant findings[J]. Curr Neuropharmacol, 2022, 20 (9): 1736- 1751.
63	Cazzola M, Calzetta L, Matera MG, et al. How does race/ethnicity influence pharmacological response to asthma therapies ?[J]. Expert Opin Drug Metab Toxicol, 2018, 14 (4): 435- 446.
64	Liu B, Yuan M, Yang M, et al. The effect of high-altitude hypoxia on neuropsychiatric functions[J]. High Alt Med Biol, 2024, 25 (1): 26- 41. doi: 10.1089/ham.2022.0136
65	Jordan IK, Sharma S, Nagar SD, et al. The apportionment of pharmacogenomic variation: race, ethnicity, and adverse drug reactions [J]. Med Res Arch, 2022, 10(9). 10.18103/mra. v10i9.2986.
66	Lin S, Xian Y, Liu Y, et al. Risk factors and community intervention for nonalcoholic fatty liver disease in community residents of Urumqi, China[J]. Medicine(Baltimore), 2018, 97 (9): e0021. doi: 10.1097/md.0000000000010021
67	Duan M, Xi Y, Tian Q, et al. Prevalence, awareness, treatment and control of type 2 diabetes and its determinants among Mongolians in China: a cross-sectional analysis of IMAGINS 2015-2020[J]. BMJ Open, 2022, 12 (11): e063893. doi: 10.1136/bmjopen-2022-063893
68	Mohamed ME, Saqr A, Staley C, et al. Pharmacomicrobiomics: immunosuppressive drugs and microbiome interactions in transplantation[J]. Transplantation, 2024, 108 (9): 1895- 1910. doi: 10.1097/TP.0000000000004926
69	Bharani T, Mogensen KM, Rosen JH, et al. Concomitant use of monoamine oxidase inhibitor and tyrosine in parenteral nutrition[J]. Eur J Clin Nutr, 2024, 78 (3): 274- 276. doi: 10.1038/s41430-023-01375-8
70	Chen Y, Xia Q, Song C, et al. Study on the hepatoxicity mechanisms of Huangyaozi (Rhizoma dioscoreae bulbiferae) on mouse liver by cDNA microarray[J]. Fen Zi Xi Bao Sheng Wu Xue Bao, 2006, 39 (6): 568- 572.
71	Iranshahy M, Iranshahi M. Traditional uses, phytochemistry and pharmacology of asafoetida (Ferula assa-foetida oleo-gum-resin)-a review[J]. J Ethnopharmacol, 2011, 134 (1): 1- 10. doi: 10.1016/j.jep.2010.11.067
72	Liu J, Zhang F, Ravikanth V, et al. Chemical Compositions of Metals in Bhasmas and Tibetan Zuotai Are a Major Determinant of Their Therapeutic Effects and Toxicity[J]. Evid Based Complement Alternat Med, 2019, 2019, 1697804. doi: 10.1155/2019/1697804
73	Cui C, Li X, Liang H, et al. Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients[J]. Biopharm Drug Dispos, 2021, 42 (1): 24- 34. doi: 10.1002/bdd.2258
74	Cui C, Valerie Sia JE, Tu S, et al. Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects[J]. Br J Clin Pharmacol, 2021, 87 (7): 2711- 2722. doi: 10.1111/bcp.14609
75	El-Khateeb E, Burkhill S, Murby S, et al. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms[J]. Biopharm Drug Dispos, 2021, 42 (4): 107- 117.
76	Li Y, Li X, Zhu M, et al. Development of a Physiologically Based Pharmacokinetic Population Model for Diabetic Patients and its Application to Understand Disease-drug-drug Interactions[J]. Clin Pharmacokinet, 2024, 63 (6): 831- 845. doi: 10.1007/s40262-024-01383-2
77	Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data[J]. Nat Rev Drug Discov, 2007, 6 (2): 140- 148. doi: 10.1038/nrd2173
78	Wu Y, Kong W, Li J, et al. Development of PBPK Population Model for End-Stage Renal Disease Patients to Inform OATP1B-, BCRP-, P-gp-, and CYP3A4-Mediated Drug Disposition with Individual Influencing Factors[J]. Pharmaceutics, 2025, 17 (8): 1078. doi: 10.3390/pharmaceutics17081078
79	Yu Z, Lei Z, Yao X, et al. Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models[J]. Front Pharmacol, 2022, 13, 1065130. doi: 10.3389/fphar.2022.1065130
80	Song L, Guo X, Yang W, et al. Maternal-Fetal Physiologically Based Population Pharmacokinetics Model Development of Lopinavir/Ritonavir in HIV/HBV Co-infected Pregnant Women to Quantitatively Describe the Gestational PK Characteristics and Predict the Potential Disease-Drug-Drug Interaction (DDDI)[J]. Clin Pharmacokinet, 2025, 64 (6): 885- 898. doi: 10.1007/s40262-025-01493-5
81	Cui C, Zhang M, Yao X, et al. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model[J]. Acta Pharm Sin B, 2020, 10 (7): 1216- 1227. doi: 10.1016/j.apsb.2020.04.007
82	Zhang M, Lei Z, Yao X, et al. Model informed drug development: HSK21542 PBPK model supporting dose decisions in specific populations[J]. Eur J Pharm Sci, 2024, 196, 106763. doi: 10.1016/j.ejps.2024.106763
83	Zhang M, Zhang S, Wang L, et al. Key Factors for Improving Predictive Accuracy and Avoiding Overparameterization of the PBPK Absorption Model in Food Effect Studies of Weakly Basic Water-Insoluble Compounds in Immediate Release Formulations[J]. Pharmaceutics, 2024, 16 (10): 1324. doi: 10.3390/pharmaceutics16101324
84	Zhang L, Feng F, Wang X, et al. Dose Prediction and Pharmacokinetic Simulation of XZP-5610, a Small Molecule for NASH Therapy, Using Allometric Scaling and Physiologically Based Pharmacokinetic Models[J]. Pharmaceuticals (Basel), 2024, 17 (3): 369. doi: 10.3390/ph17030369
85	Zhang M, Yao X, Hou Z, et al. Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients[J]. Front Pharmacol, 2020, 11, 585021.
86	Zhang M, Yu Z, Yao X, et al. Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker[J]. Front Pharmacol, 2022, 13, 972411. doi: 10.3389/fphar.2022.972411
87	Bosilkovska M, Samer CF, Déglon J, et al. Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots[J]. Clin Pharmacol Ther, 2014, 96 (3): 349- 359. doi: 10.1038/clpt.2014.83
88	Donzelli M, Derungs A, Serratore MG, et al. The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots[J]. Clin Pharmacokinet, 2014, 53 (3): 271- 282. doi: 10.1007/s40262-013-0115-0
89	Stopfer P, Giessmann T, Hohl K, et al. Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin, and rosuvastatin[J]. Clin Pharmacol Ther, 2016, 100 (3): 259- 267. doi: 10.1002/cpt.406
90	Kong W, Pan Y, Wu Y, et al. Microdose cocktail study reveals the activity and key influencing factors of OATP1B, P-Gp, BCRP, and CYP3A in end-stage renal disease patients[J]. Clin Pharmacol Ther, 2025, 117 (5): 1303- 1312.
91	Valerie Sia JE, Lai X, Mak WY, et al. Aging-related CYP3A functional changes in Chinese older patients: New findings from model-based assessment of amlodipine[J]. Clin Pharmacol Ther, 2024, 116 (3): 858- 865.
92	Yoshikado T, Aoki Y, Mochizuki T, et al. Cluster gauss-Newton method analyses of PBPK model parameter combinations of coproporphyrin-I based on OATP1B-mediated rifampicin interaction studies[J]. CPT Pharmacometrics Syst Pharmacol, 2022, 11 (10): 1341- 1357.
93	Song L, Song J, Wang Y, et al. Systematic quantitative analysis of fetal dexamethasone exposure and fetal lung maturation in pregnant animals: model informed dexamethasone precision dose study[J]. ACS Pharmacol Transl Sci, 2024, 7 (6): 1770- 1782. doi: 10.1021/acsptsci.3c00391
94	Guo X, Zhang L, Lei Z, et al. A simple LC-MS/MS method for the simultaneous quantification of drug metabolic enzymes[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2023, 1214, 123536. doi: 10.1016/j.jchromb.2022.123536
95	Zhang L, Liu X, Jin T, et al. Isomers-oriented separation of forty-five plasma bile acids with liquid chromatography-tandem mass spectrometry[J]. J Chromatogr A, 2024, 1721, 464827. doi: 10.1016/j.chroma.2024.464827
96	Cui C, Fang L, Li L, et al. Odoribacter splanchnicus rescues aging-related intestinal P-glycoprotein damage via GDP-L-fucose secretion[J]. Nat Commun, 2025, 16 (1): 10665. doi: 10.1038/s41467-025-65692-1

[1]	CHEN Guihai, DENG Liying, DU Yijie, HUANG Zhili, JIANG Fan, JIN Furui, LI Yanpeng, LIU Chunfeng, PAN Jiyang, PENG Yanhui, SU Changjun, TANG Jiyou, WANG Tao, WANG Zan, WU Huijuan, XUE Rong, YANG Yuechang, YU Fengchun, YU Huan, ZHAN Shuqin, ZHANG Hongju, ZHANG Lin, ZHAO Zhengqing, ZHAO Zhongxin. Expert consensus on the diagnosis and treatment of insomnia in specified populations [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(8): 841-852.
[2]	YUAN Shixuan, LV Ziyan, YANG Yong, CHEN Lu, ZHANG Lijuan. Clinical study on model-guided vancomycin plasma concentration monitoring [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(12): 1344-1352.
[3]	TAO Shaoneng, GE Junliang, YANG Jiwen, CHEN Xiaolei, YIN Weili, WANG Yingying, LIU Xiaocen. Analysis of the efficacy and influencing factors after the First 131I treatment after surgery for differentiated thyroid cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(12): 1435-1440.
[4]	WANG Xin, WU Guodong, AN Ming, LI Gang, LIU Yang. Advances in venlafaxine-related PK-PD relationship and influencing factors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 788-795.
[5]	QIAN Jin, WANG Fengyan. Influence factors of serum NT-proBNP level in elderly patients with acute myocardial infarction after PCI and its influence on short-term prognosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 658-665.
[6]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.
[7]	PENG Min, HUANG Panhao, DENG Yinhua, LIU Wen, LI Wei, YU Zhen, XIA Qing, XIE Yueliang. Analysis of influence factors of voriconazole trough concentration in patients with hematopoietic stem cell transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 640-646.
[8]	JIAO Zheng, LI Xingang, SHANG Dewei, DONG Jing, ZUO Xiaocong, CHEN Bing, LIU Jianmin, PAN Yan, ZHOU Tianyan, ZHANG Jing, LIU Dongyang, LI Lujin, FANG Yi, MA Guangli, DING Junjie, ZHAO Wei, CHEN Rui, XIANG Xiaoqiang, WANG Yuzhu, GAO Jianjun, XIE Haitang, HU Pei, ZHENG Qingshan. Model informed precision dosing: China expert consensus report [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1215-1228.
[9]	LI Lujin, DING Junjie, LIU Dongyang, WANG Xipei, DENG Chenhui, JI Shangmin, CHEN Wenjun, MA Guangli, WANG Kun, SHENG Yucheng, XU Ling, PEI Qi, CHEN Yuancheng, CHEN Rui, SHI Jun, LI Gailing, WANG Yaning, WANG Yuzhu, XIE Haitang, ZHOU Tianyan, FANG Yi, ZHANG Jing, JIAO Zheng, HU Bei, ZHENG Qingshan. General considerations of model-based meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1250-1267.
[10]	LIU Simin, CAI Jun, LI Huixin, YANG Li, ZHAO Yan, ZHANG Jinping. Research progress in population pharmacokinetics of voriconazole in adults [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1015-1023.
[11]	MA Guangli, XU Ling, CHEN Rui, CHEN Yuancheng, ZHAO Wei, LIU Dongyang, JIAO Zheng, LI Jian, JI Shuangmin, LI Li, LI Liang, WANG Yuzhu, YANG Jinbo, WANG Yaning, SUN He, HU Pei, ZHENG Qingshan, LU Wei. General considerations of population pharmacokinetic/pharmacodynamic study in new drug development [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1201-1220.
[12]	LIU Dongyang,WANG Kun,MA Guangli,XIANG Xiaoqiang,LIU Jiang,ZHAO Ping,CHEN Rui,CHEN Yuancheng,HUANG Xiaohui, LI Li,LI Lujin,NIE Jing,WANG Yuzhu,WEI Chunmin,LU Wei,SHI Jun, ZHENG Qingshan. The value and general consideration of pharmacometric study in new drug development [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 961-973.
[13]	LI Guo-zhu, XIE Hai-tang, CHEN Bai-feng, WANG Hao, SUN Xiao-tian. A survey on adult medication compliance and its influencing factors analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 47-50.